File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Association between HLA-B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong

TitleAssociation between HLA-B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong
Authors
Issue Date2012
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/BJD
Citation
British Journal Of Dermatology, 2012, v. 167 n. 1, p. 44-49 How to Cite?
AbstractBackground: Allopurinol has been reported as a common cause of severe cutaneous adverse reactions (SCARs). Recent studies in various populations suggest that HLA-B*58:01 is a strong genetic marker for allopurinol-induced SCAR, especially in populations with a high frequency of HLA-B*58:01. Objectives: To confirm the association link between HLA-B*58:01 and hypersensitivity reactions attributed to allopurinol use in Han Chinese patients in Hong Kong. Methods: We performed a case-control study to investigate whether the HLAB*58:01 allele predisposes to allopurinol-induced SCAR in Han Chinese patients in Hong Kong. The HLA-B*58:01 genotyping was performed in 20 patients with allopurinol-induced SCAR or erythema multiforme major (EMM; n = 1) and in 30 patients tolerant to allopurinol. Results: All of the 19 patients with allopurinol-induced SCAR examined but not the patient with EMM carried HLA-B*58:01 whereas only four (13%) of the control patients had this allele. The positive rate of the HLA-B*58:01 was significantly higher in the cases than in the allopurinol-tolerant control group [odds ratio (OR) 123.5, 95% confidence interval (CI) 12.8-1195.1; P < 1 × 10 -4] and was even higher after removal of the patient with EMM (OR 229.7, 95% CI 11.7-4520.4). The sensitivity and specificity of the HLA-B*58:01 allele for prediction of allopurinol-induced SCAR were 100% and 86.7%, respectively. Conclusions: This study confirmed the strong association between the HLA-B*58:01 and allopurinol-induced SCAR in Hong Kong Han Chinese patients. A screening test for the HLA-B*58:01 allele should effectively reduce the risk for allopurinol-induced SCAR in Chinese populations. © 2012 The Authors BJD © 2012 British Association of Dermatologists 2012.
Persistent Identifierhttp://hdl.handle.net/10722/182351
ISSN
2015 Impact Factor: 4.317
2015 SCImago Journal Rankings: 2.021
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChiu, MLSen_US
dc.contributor.authorHu, Men_US
dc.contributor.authorNg, MHLen_US
dc.contributor.authorYeung, CKen_US
dc.contributor.authorChan, JCYen_US
dc.contributor.authorChang, MMen_US
dc.contributor.authorCheng, SHen_US
dc.contributor.authorLi, Len_US
dc.contributor.authorTomlinson, Ben_US
dc.date.accessioned2013-04-23T08:19:47Z-
dc.date.available2013-04-23T08:19:47Z-
dc.date.issued2012en_US
dc.identifier.citationBritish Journal Of Dermatology, 2012, v. 167 n. 1, p. 44-49en_US
dc.identifier.issn0007-0963en_US
dc.identifier.urihttp://hdl.handle.net/10722/182351-
dc.description.abstractBackground: Allopurinol has been reported as a common cause of severe cutaneous adverse reactions (SCARs). Recent studies in various populations suggest that HLA-B*58:01 is a strong genetic marker for allopurinol-induced SCAR, especially in populations with a high frequency of HLA-B*58:01. Objectives: To confirm the association link between HLA-B*58:01 and hypersensitivity reactions attributed to allopurinol use in Han Chinese patients in Hong Kong. Methods: We performed a case-control study to investigate whether the HLAB*58:01 allele predisposes to allopurinol-induced SCAR in Han Chinese patients in Hong Kong. The HLA-B*58:01 genotyping was performed in 20 patients with allopurinol-induced SCAR or erythema multiforme major (EMM; n = 1) and in 30 patients tolerant to allopurinol. Results: All of the 19 patients with allopurinol-induced SCAR examined but not the patient with EMM carried HLA-B*58:01 whereas only four (13%) of the control patients had this allele. The positive rate of the HLA-B*58:01 was significantly higher in the cases than in the allopurinol-tolerant control group [odds ratio (OR) 123.5, 95% confidence interval (CI) 12.8-1195.1; P < 1 × 10 -4] and was even higher after removal of the patient with EMM (OR 229.7, 95% CI 11.7-4520.4). The sensitivity and specificity of the HLA-B*58:01 allele for prediction of allopurinol-induced SCAR were 100% and 86.7%, respectively. Conclusions: This study confirmed the strong association between the HLA-B*58:01 and allopurinol-induced SCAR in Hong Kong Han Chinese patients. A screening test for the HLA-B*58:01 allele should effectively reduce the risk for allopurinol-induced SCAR in Chinese populations. © 2012 The Authors BJD © 2012 British Association of Dermatologists 2012.en_US
dc.languageengen_US
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/BJDen_US
dc.relation.ispartofBritish Journal of Dermatologyen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 And Overen_US
dc.subject.meshAllopurinol - Adverse Effectsen_US
dc.subject.meshAsian Continental Ancestry Group - Ethnologyen_US
dc.subject.meshCase-Control Studiesen_US
dc.subject.meshDrug Eruptions - Ethnology - Geneticsen_US
dc.subject.meshFemaleen_US
dc.subject.meshGenetic Predisposition To Disease - Ethnology - Geneticsen_US
dc.subject.meshGenotypeen_US
dc.subject.meshHla-B Antigens - Geneticsen_US
dc.subject.meshHong Kong - Ethnologyen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshUricosuric Agents - Therapeutic Useen_US
dc.titleAssociation between HLA-B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kongen_US
dc.typeArticleen_US
dc.identifier.emailChan, JCY: johnny7241980@gmail.comen_US
dc.identifier.authorityChan, JCY=rp01737en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1111/j.1365-2133.2012.10894.xen_US
dc.identifier.pmid22348415-
dc.identifier.scopuseid_2-s2.0-84863335462en_US
dc.identifier.hkuros217341-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84863335462&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume167en_US
dc.identifier.issue1en_US
dc.identifier.spage44en_US
dc.identifier.epage49en_US
dc.identifier.isiWOS:000305791500010-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridChiu, MLS=12779305700en_US
dc.identifier.scopusauthoridHu, M=35110331400en_US
dc.identifier.scopusauthoridNg, MHL=35292609300en_US
dc.identifier.scopusauthoridYeung, CK=55158726200en_US
dc.identifier.scopusauthoridChan, JCY=37664694100en_US
dc.identifier.scopusauthoridChang, MM=26641031800en_US
dc.identifier.scopusauthoridCheng, SH=7404681588en_US
dc.identifier.scopusauthoridLi, L=34978594900en_US
dc.identifier.scopusauthoridTomlinson, B=54911672100en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats